References
- Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis. COCHRANE DATABASE Syst Rev. 2016. Published Online First. doi:https://doi.org/10.1002/14651858.CD010469.pub2.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516. doi:https://doi.org/10.1016/j.ajo.2005.03.057.
- Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26:2–16. doi:https://doi.org/10.1080/09273948.2016.1196713.
- Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the United States a claims-based analysis. JAMA Ophthalmol. 2016;134:1237–1245. doi:https://doi.org/10.1001/jamaophthalmol.2016.3229.
- Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–848. doi:https://doi.org/10.1136/bjo.80.9.844.
- Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage – proceedings of an expert panel roundtable discussion. Retin J Retin Vitr Dis. 2006;26(8):1–16.
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513. doi:https://doi.org/10.1016/s0002-9394(00)00659-0.
- Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals of Care for UveitiS (FOCUS) initiative. Ophthalmology. 2018;125:757–773. doi:https://doi.org/10.1016/j.ophtha.2017.11.017.
- Uchiyama E, Papaliodis GN, Lobo A-M, et al. Side-effects of anti-inflammatory therapy in uveitis. Semin Ophthalmol. 2014;29:456–467. doi:https://doi.org/10.3109/08820538.2014.959203.
- Foster CS, Kothari S, Anesi SD, et al. The ocular immunology and uveitis foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61:1–17. doi:https://doi.org/10.1016/j.survophthal.2015.07.001.
- de Oliveira Dias JR, Nunes RP, Goldhardt R. New drugs and new posterior delivery methods in CME. Curr Ophthalmol Rep. 2017;5:160–168. doi:https://doi.org/10.1007/s40135-017-0134-3.
- Pouwels XGL V, Petersohn S, Carrera VH, et al. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2019 Nov. Published Online First. doi:https://doi.org/10.1007/s40273-019-00851-z.
- Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment twelve-month results. Ophthalmology. 2019;126:601–610. doi:https://doi.org/10.1016/j.ophtha.2018.10.033.
- Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553. doi:https://doi.org/10.1001/archophthalmol.2010.339.
- Infarmed. Autoridade Nacional do Medicamento e Produtos de Saúde. Lisbon: Resumo das Características do Medicamento; 2019. http://app7.infarmed.pt/infomed/download_ficheiro.php?med_id=52065&tipo_doc=rcm
- Huwaldt JA, Steinhorst S. Plot Digitizer (Version 2.6.8). 2015. http://plotdigitizer.sourceforge.net
- Koh WM, Bogich T, Siegel K, et al. The epidemiology of hand, foot and mouth disease in Asia: a systematic review and analysis. Pediatr Infect Dis J. 2016;35:e285–300. doi:https://doi.org/10.1097/INF.0000000000001242.
- Pisegna JM, Kaneoka A, Pearson WGJ, et al. Effects of non-invasive brain stimulation on post-stroke dysphagia: a systematic review and meta-analysis of randomized controlled trials. Clin Neurophysiol. 2016;127:956–968. doi:https://doi.org/10.1016/j.clinph.2015.04.069.
- Parker EPK, Kampmann B, Kang G, et al. Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J Infect Dis. 2014;210:853–864. doi:https://doi.org/10.1093/infdis/jiu182.
- Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. doi:https://doi.org/10.1136/bmj.l4898.
- Institute of Social and Preventive Medicine - University of Bern. CINeMA: confidence in network meta-analysis. 2017. https://cinema.ispm.unibe.ch
- Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118:1916–1926. doi:https://doi.org/10.1016/j.ophtha.2011.07.027.
- Sangwan VSPPAPH, Comstock TL, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther. 2015;4:1–19. doi:https://doi.org/10.1007/s40123-014-0027-6.
- Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant - three-year clinical trial results. Arch Ophthalmol. 2008;126:1191–1201. doi:https://doi.org/10.1001/archopht.126.9.1191.
- Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–U194. doi:https://doi.org/10.1016/j.ophtha.2009.11.027.
- Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126:283–295. doi:https://doi.org/10.1016/j.ophtha.2018.08.021.
- Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA, Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317:1993–2005. doi:https://doi.org/10.1001/jama.2017.5103.